Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-179, BRII-835 and PEG-IFNα in Chronic Hepatitis B Virus (HBV) Infection
NCT06650852Phase 2Recruiting
- Sponsor
- Brii Biosciences
- Start
- Oct 2024
- Primary completion
- Sep 2028
- Modality
- Recombinant Protein Vaccines, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of BRII-179, elebsiran in chronic hepatitis B virus infection (CHB), sponsored by Brii Biosciences. Started Oct 2024; status: recruiting.
02
Drugs
BRII-179elebsiran
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT06650852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650852.